The KSHV G protein-coupled receptor signals via multiple pathways to induce transcription factor activation in primary effusion lymphoma cells

被引:65
作者
Cannon, ML
Cesarman, E
机构
[1] Cornell Univ, Weill Med Coll, Dept Med, Div Int Med & Infect Dis, New York, NY 10021 USA
[2] Cornell Univ, Weill Med Coll, Dept Pathol, New York, NY 10021 USA
关键词
Kaposi's sarcoma-associated virus (KSHV); G protein-coupled receptor (GPCR); primary effusion lymphoma (PEL); signaling;
D O I
10.1038/sj.onc.1207021
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Kaposi#39;s sarcoma-associated virus (KSHV) is the causative agent of Kaposi#39;s sarcoma (KS) and primary effusion lymphoma (PEL). The KSHV G protein-couple receptor (vGPCR) is a homologue of the human IL-8 receptor that signals constitutively, activates mitogen- and stress-activated kinases, and induces transcription via multiple transcription factors including AP-1 and NF#954;B. Furthermore, vGPCR causes cellular transformation in vitro and leads to KS-like tumors in transgenic mouse models. vGPCR has therefore become an exciting potential therapeutic target for KSHV-mediated disease, but its signaling properties need to be better understood in the context of KSHV-infected hematopoietic cells. We recently described a PEL cell line that expresses vGPCR via an inducible promoter and have shown that vGPCR has broad capabilities of affecting cellular and viral transcription patterns in this highly relevant cell type. To elucidate the predominant signaling pathways used by vGPCR in PEL cells, we have used reporter gene assays to measure vGPCR activity in the presence of various pharmacologic enzyme inhibitors and plasmid constructs. We show that vGPCR-induced activation of AP-1 and CREB is mediated cooperatively by a Gq-ERK-1#47;2 and a Gi#8211;PI3K-Src axis. Furthermore, unlike in other cell types, NF#954;B activation by vGPCR seems not to be substantially mediated by Gi or PI3K#47;Akt in PEL cells.Oncogene (2004) 23, 514#8211;523. doi:10.1038/sj.onc.1207021
引用
收藏
页码:514 / 523
页数:10
相关论文
共 80 条
  • [1] AHUJA SK, 1993, J BIOL CHEM, V268, P20691
  • [2] Role of vascular endothelial growth factor/vascular permeability factor in the pathogenesis of Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphomas
    Aoki, Y
    Tosato, G
    [J]. BLOOD, 1999, 94 (12) : 4247 - 4254
  • [3] Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6
    Aoki, Y
    Jaffe, ES
    Chang, Y
    Jones, K
    Teruya-Feldstein, J
    Moore, PS
    Tosato, G
    [J]. BLOOD, 1999, 93 (12) : 4034 - 4043
  • [4] Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation
    Arvanitakis, L
    GerasRaaka, E
    Varma, A
    Gershengorn, MC
    Cesarman, E
    [J]. NATURE, 1997, 385 (6614) : 347 - 350
  • [5] Constitutively signaling G-protein-coupled receptors and human disease
    Arvanitakis, L
    Geras-Raaka, E
    Gershengorn, MC
    [J]. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1998, 9 (01) : 27 - 31
  • [6] BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141
  • [7] Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/KDR
    Bais, C
    Van Geelen, A
    Eroles, P
    Mutlu, A
    Chiozzini, C
    Dias, S
    Silverstein, RL
    Rafii, S
    Mesri, EA
    [J]. CANCER CELL, 2003, 3 (02) : 131 - 143
  • [8] G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator
    Bais, C
    Santomasso, B
    Coso, O
    Arvanitakis, L
    Raaka, EG
    Gutkind, JS
    Asch, AS
    Cesarman, E
    Gerhengorn, MC
    Mesri, EA
    [J]. NATURE, 1998, 391 (6662) : 86 - 89
  • [9] KAPOSIS SARCOMA-ASSOCIATED HERPESVIRUS INFECTS ENDOTHELIAL AND SPINDLE CELLS
    BOSHOFF, C
    SCHULZ, TF
    KENNEDY, MM
    GRAHAM, AK
    FISHER, C
    THOMAS, A
    MCGEE, JO
    WEISS, RA
    OLEARY, JJ
    [J]. NATURE MEDICINE, 1995, 1 (12) : 1274 - 1278
  • [10] Burger M, 1999, J IMMUNOL, V163, P2017